Greenwich LifeSciences, Inc.
- GLSI
- NASDAQ
- Biotechnology
- Cancer Immunotherapy (HER2)
- Clinical-Stage Biotech
$15.21
Today +4.54%Quote Oct 19, 2026, 08:00 PM UTC
−19.91%over the last month
Max drawdown −25.3%From 1-month high −21.9%3 months +3.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Greenwich LifeSciences
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
13
Founded
2006
Market value
$223.3M
Quote Oct 19
Analyst target
$50.00
+228.7% from here
Floor
$15.07
0.9% below price
Resistance
$15.54
2.1% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about GLSIPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free